A Study of DU-176b in Preventing Blood Clots After Hip Replacement Surgery

• Status: Completed
• Trial end date: 2007-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is to assess if DU176b is effective in prevention of blood clots following hip replacement surgery. The duration is 7-10 days of treatment and 30 and 60 day follow-up visits.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daiichi Sankyo Inc.; Daiichi Sankyo, Inc.
• Treatments: Edoxaban; Factor Xa Inhibitors

Criteria

1. 18 years of age or older; male or female.

2. Able to provide written informed consent.

3. Must be scheduled for elective unilateral total hip replacement surgery. Only primary surgeries accepted.

4. If female, must be either one year post-menopausal, surgically sterile, or using medically accepted contraceptive measures as judged by the Investigator and in accordance with local regulatory requirements.